Ensuring Access to Essential Drugs Act
Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · Mar 6, 2025
View full text on Congress.gov ↗ Policy area: Health
Ensuring Access to Essential Drugs Act This bill exempts certain brand-name drugs from the Medicare Part D Manufacturer Discount Program. Under the program, drug manufacturers provide discounts to beneficiaries who have incurred costs above the annual deductible under the Medicare prescription drug benefit. Specifically, the bill exempts from the program orally administered, brand-name drugs that are considered generics for purposes of the Medicaid Drug Rebate Program (per an exception granted by the Centers for Medicare & Medicaid Services).
Source: Congressional Research Service (CRS).
Track HR 1922 in BallotBox360
Get real-time bill updates, floor vote alerts, and AI-powered summaries — all in one app.
Download on iOS Open Web App